Abstract
A phase-change material (PCM) is an efficient energy storage material, but its poor thermal conductivity has limited its application in nanomedicine research. In this study, we used the photothermal material copper sulfide (CuS) to tackle this challenge. The designed CuS-DOX-MBA@PCM nanoparticles (NPs) were prepared by a nanoprecipitation method, and were composed of CuS, the anticancer drug (DOX), and near-infrared (NIR) dyes (MBA) encapsulated with stearic acid and lauric acid, which are characterized by a low eutectic point close to human physiological temperature. Because the CuS-DOX-MBA@PCM NPs could release the drug quickly in physiological conditions, it implied that they could have potential as a promising drug-loading system. CuS-DOX-MBA@PCM NPs were utilized as an imaging-guided photothermal agent for photothermal therapy (PTT) combined with chemotherapy in cells and in a mice model.
In vitro
fluorescence imaging indicated the high uptake of CuS-DOX-MBA@PCM NPs in tumor cells due to enhanced permeability and retention effects, while
in vivo
experiments showed that the tumor growth in tumor-bearing mice models could be inhibited by the CuS-DOX-MBA@PCM NPs. Such an evident enhanced tumor inhibition could be attributed to the synergistic effect of the DOX chemotherapy and the photothermal therapy with a safe laser irradiation at 808 nm with a power density of 1.0 W cm
−2
. Furthermore, this combined therapy offers the possibility to lower the dosage of DOX in anticancer therapy, which would thus decrease the toxic effects on cancer patients. The results from this study confirmed the effect of CuS-DOX-MBA@PCM NPs for use as a chemo–photothermal therapy and the clinical value of the designed thermosensitive drug-loading system in the field of combined cancer therapy.